Today: 9 June 2026
Browse Category

LSE:ULVR 16 November 2025 - 8 December 2025

Biggest UK Stock Losers Today: FTSE 100, Mid‑Caps and AIM Names Under Pressure (8 December 2025)

Biggest UK Stock Losers Today: FTSE 100, Mid‑Caps and AIM Names Under Pressure (8 December 2025)

UK shares fell sharply Monday, 8 December 2025, with FTSE 100 futures down 0.1% after a 0.5% drop Friday. Everest Global PLC plunged about 38%, leading losses among small-cap and AIM stocks. Traders cited caution ahead of US Federal Reserve and Reserve Bank of Australia meetings, and a possible Bank of England rate cut later in December. Barclays’ potential Evelyn Partners deal and Trustpilot faced extra scrutiny.
8 December 2025
····
Unilever PLC Stock (ULVR, UL) on 5 December 2025: Share Price, Magnum Ice Cream Spin‑Off and 2026 Outlook

Unilever PLC Stock (ULVR, UL) on 5 December 2025: Share Price, Magnum Ice Cream Spin‑Off and 2026 Outlook

Unilever shares closed flat in London on 5 December at around 4,430p, with a market value near £110 billion, as the company prepares to spin off its ice-cream business. The Magnum Ice Cream Company demerger is set to complete on 6 December, with TMICC shares trading from 8 December in Amsterdam, London, and New York. Unilever will retain a 19.9% stake in TMICC, to be sold down over time. Share consolidation takes effect 9 December.
5 December 2025
··
Unilever PLC Stock in December 2025: Magnum Spin‑Off, Graze Sale, Share Cancellation and What Analysts Expect Next

Unilever PLC Stock in December 2025: Magnum Spin‑Off, Graze Sale, Share Cancellation and What Analysts Expect Next

Unilever shares traded at 4,425p–4,450p in London and $59.4 in New York on December 4, 2025, near year lows. The Magnum Ice Cream spin-off is set to complete December 6, with TMICC shares listing in Amsterdam and London on December 8. Unilever will consolidate shares after the demerger. The company’s trailing P/E stands at 22–23, with a dividend yield around 3–3.5%.
4 December 2025
·
Unilever PLC Stock on 3 December 2025: Magnum Spin‑Off, Graze Sale and Governance Scrutiny Shape the Outlook

Unilever PLC Stock on 3 December 2025: Magnum Spin‑Off, Graze Sale and Governance Scrutiny Shape the Outlook

Unilever shares traded at 4,477p in London on December 3, down 4.6% over 12 months, as the company prepares to spin off its ice cream unit, The Magnum Ice Cream Company. The demerger is set for completion around December 6, with Magnum shares to debut in Amsterdam, London, and New York. Unilever will retain 19.9% of TMICC, which has raised €3 billion in its first bond sale.
3 December 2025
···
Unilever PLC Stock (ULVR, UL): Graze Sale, Magnum Ice Cream Spin‑Off and the December 2025 Outlook

Unilever PLC Stock (ULVR, UL): Graze Sale, Magnum Ice Cream Spin‑Off and the December 2025 Outlook

Unilever has agreed to sell its Graze snack brand to Germany’s Katjes International, with closing expected in the first half of 2026. The move comes as Unilever weighs divesting British staples Marmite and Bovril and prepares to spin off its Magnum ice cream unit. London shares last closed at 4,559p, valuing the group at £112 billion. The company reported over €6 billion in net profit for 2024.
2 December 2025
··
UK Stock Market Today: FTSE 100 Slips as Risk-Off Mood Starts December in London

UK Stock Market Today: FTSE 100 Slips as Risk-Off Mood Starts December in London

The FTSE 100 slipped 0.1–0.2% to around 9,700 by early afternoon in London on December 1, while the FTSE 250 dropped 0.8%, its sharpest fall in two weeks. Mining stocks climbed over 5% as gold and silver prices rose, but aerospace, defence, and major banks declined. Homebuilders in the FTSE 250 fell more than 1.5% amid concerns over higher borrowing costs and weak services data.
1 December 2025
·······
UK Stock Market Today: FTSE 100 Flat, Mid‑Caps Slide as Risk‑Off Mood Opens December – 1 December 2025

UK Stock Market Today: FTSE 100 Flat, Mid‑Caps Slide as Risk‑Off Mood Opens December – 1 December 2025

The FTSE 100 held near record highs on Monday, trading at 9,718 by early afternoon, down just 0.03%. The FTSE 250 slid 0.8%, its sharpest fall in two weeks, as investors sold off mid-cap and cyclical stocks. Gold miners surged more than 5% as bullion hit a six-week high. Rolls-Royce fell 3%, while HICL Infrastructure rose 4.4%.
1 December 2025
········
Unilever PLC Stock on 1 December 2025: Magnum Spin‑Off, Marmite Sale Talk and What Analysts Expect Next

Unilever PLC Stock on 1 December 2025: Magnum Spin‑Off, Marmite Sale Talk and What Analysts Expect Next

Unilever will spin off its €15 billion ice-cream unit, The Magnum Ice Cream Company, on 6 December 2025. Shares in London, New York, and Amsterdam all traded mid-range as of late November, with a dividend yield near 3.3–3.5%. Unilever reaffirmed full-year guidance after solid Q3 results and is considering selling British brands including Marmite. Share consolidation follows the spin-off on 9 December.
1 December 2025
···
Unilever PLC Stock on 28 November 2025: JPMorgan Ups Target as Magnum Spin-Off and New Bonds Take Center Stage

Unilever PLC Stock on 28 November 2025: JPMorgan Ups Target as Magnum Spin-Off and New Bonds Take Center Stage

JPMorgan raised its target price for Unilever’s London shares to 5,700p, implying 26% upside, citing the planned Magnum Ice Cream spin-off and productivity gains. Unilever’s London shares closed at about 4,520p on 27 November, while its New York ADR finished at $60.20. The company’s market cap stands near £110 billion, with a Q3 dividend of €0.4528 per share due 5 December.
28 November 2025
··
Unilever (ULVR) Today: Magnum Ice Cream Spin‑Off, €3bn Bond Deal and Split Analyst Views – 27 November 2025

Unilever (ULVR) Today: Magnum Ice Cream Spin‑Off, €3bn Bond Deal and Split Analyst Views – 27 November 2025

Unilever’s ice cream unit TMICC completed a €3 billion bond sale ahead of its planned spin-off, set for 6 December, with TMICC shares to debut in Amsterdam on 8 December. Unilever shares closed flat at 4,521p in London Thursday on light volume. Analyst ratings remain split, while institutional investors increased stakes. The group will pay a €0.4528 Q3 dividend, with Q4 payout expected post-demerger.
27 November 2025
··
Unilever PLC (ULVR) News Today: Share Price Softens as Graze Sale, HUL Profit Push and Magnum Spin‑Off Shape Outlook – 26 November 2025

Unilever PLC (ULVR) News Today: Share Price Softens as Graze Sale, HUL Profit Push and Magnum Spin‑Off Shape Outlook – 26 November 2025

Unilever shares fell 0.6% in London to 4,525p by mid-morning Wednesday after news of a planned £35m sale of its Graze snack brand to Katjes Group, far below the £150m paid in 2019. The company is also considering selling British staples like Marmite and has instructed Hindustan Unilever to pursue higher-margin growth. Analyst ratings remain mixed despite recent price target increases.
26 November 2025
··
Unilever (ULVR) share price: what to know before the London market opens on 17 November 2025

Unilever (ULVR) share price: what to know before the London market opens on 17 November 2025

Unilever closed Friday at 4,470p, down 2.06%, slipping below key moving averages. The company reconfirmed its ice-cream demerger timetable, with TMICC’s market debut set for 8 December and a Unilever share consolidation expected on 9 December. Unilever’s NYSE ADR edged up 0.19% after hours. A Ben & Jerry’s board dispute remains unresolved ahead of the spin-off.
16 November 2025
··
1 2 3 4

Stock Market Today

  • Broadcom Stock Set for 27% Gain to $500 Amid AI Growth, Despite Recent Selloff
    June 9, 2026, 10:08 AM EDT. Broadcom (NASDAQ:AVGO) shares dropped nearly 14% post-earnings despite 47.87% revenue growth and an eighth straight earnings per share (EPS) beat. The stock trades around $396.60, with a 24/7 Wall St. price target of $503.61, implying a 26.98% upside over 12 months and a buy recommendation at 90% confidence. Broadcom's Q2 revenue hit $22.19 billion with a 143% jump in AI semiconductor sales to $10.8 billion. CEO Hock Tan projects over 200% AI revenue growth in Q3, targeting $16 billion. Bear risks include heavy insider selling and a high 64 forward P/E ratio. Bulls note strong AI demand, with price targets up to $600 billion revenue potential by 2028. The stock remains 14.82% higher year-to-date despite recent volatility.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Go toTop